Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Xenon Pharmaceuticals Inc. Common Shares (XENE)

NASDAQ: XENE · Pharmaceutical Preparations · Burnaby,

Our rating: Neutral

Call changed from Cautious to Neutral at $41.39, moderate conviction, November 10, 2026.

Breaks if: The Neutral call breaks toward Cautious if annual FCF burn accelerates beyond $380M across the next four reported quarters or a lead clinical program misses its primary endpoint in the next 12 months. It breaks toward Positive if Xenon secures a Phase 3 success or receives an FDA approval — or a confirmed PDUFA date — that converts pipeline probability into near-certain commercial revenue within the same 12-month window.

Key figures

Market value$3.6B
Revenue, last 12 months$0.00
Net income, last 12 months−$429M
Free cash flow, last 12 months−$357M
Price to earningsn/a
Free cash flow yield−9.8%
Dividend yield0.0%
Operating marginn/a
Return on equity−50.3%
Beta to the S&P 5000.88
Volatility, annualized53.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$0.00n/a$-1.11−$91M
June 30, 2026$0.00n/a$-1.11−$96M
March 31, 2026$0.00−100.0%$-1.17−$89M
December 31, 2025$0.00n/a$-1.31−$82M
September 30, 2025$0.00n/a$-1.15−$72M
June 30, 2025$0.00n/a$-1.07−$64M
March 31, 2025$8Mn/a$-0.83−$62M
December 31, 2024$0.00n/a$-0.84−$55M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 50 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.